期刊
JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
卷 70, 期 -, 页码 145-151出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jiec.2018.09.052
关键词
Beta-cyclodextrin (beta-CD); Polyethylene glycol (PEG); Folic acid (FA); Doxorubicin (DOX); Breast cancer therapy
资金
- National Research Foundation of Korea (NRF) [NRF-2018R1A2B6009283, 2014R1A1A1002697, 2017R1D1A1B03033195, 2016R1A2B4014600, 2017R1D1A1A02018640]
- Technology Innovation Program - Ministry of Trade, Industry, and Energy (MOTIE, Republic of Korea) [10053595]
- National Research Foundation of Korea [2016R1A2B4014600, 2014R1A1A1002697, 2017R1D1A1A02018640, 2017R1D1A1B03033195] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
In this study, we prepared a beta-cyclodextrin (beta-CD)-based carrier consisting of beta-CD, polyethylene glycol (PEG) and folic acid (FA) (CDPF) for improved doxorubicin (DOX) delivery to targeted breast cancer in vitro and in vivo. The morphology and size distribution were characterized by transmission electron microscopy (TEM) and dynamic light scattering (DLS) measurements, which revealed in particles ranging from 38 nm to 52 nm in size. DOX from CDPF was released in a sustained manner for 48 h. Cell viability analysis showed the low toxicity of free DOX, whereas CDPF-DOX remarkably exhibited reduced viability after incubation for 7 days. In vivo animal test showed that intravenous injection of CDPF-DOX contributes to decreased tumor volume, along with no systemic toxicity and cardiotoxicity. The results suggested that CDPF can maximize the efficacy of DOX delivery; therefore can be used as a good candidate for developing optimal drug delivery systems. (C) 2018 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据